JP2021526509A5 - - Google Patents
Info
- Publication number
- JP2021526509A5 JP2021526509A5 JP2020564389A JP2020564389A JP2021526509A5 JP 2021526509 A5 JP2021526509 A5 JP 2021526509A5 JP 2020564389 A JP2020564389 A JP 2020564389A JP 2020564389 A JP2020564389 A JP 2020564389A JP 2021526509 A5 JP2021526509 A5 JP 2021526509A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- cancer
- seq
- sequence shown
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023093016A JP7662707B2 (ja) | 2018-05-14 | 2023-06-06 | 抗cd24組成物及びその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862671193P | 2018-05-14 | 2018-05-14 | |
| US62/671,193 | 2018-05-14 | ||
| PCT/US2019/031983 WO2019222082A1 (en) | 2018-05-14 | 2019-05-13 | Anti-cd24 compositions and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023093016A Division JP7662707B2 (ja) | 2018-05-14 | 2023-06-06 | 抗cd24組成物及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021526509A JP2021526509A (ja) | 2021-10-07 |
| JP2021526509A5 true JP2021526509A5 (cg-RX-API-DMAC7.html) | 2022-05-19 |
| JP7294758B2 JP7294758B2 (ja) | 2023-06-20 |
Family
ID=68540727
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020564389A Active JP7294758B2 (ja) | 2018-05-14 | 2019-05-13 | 抗cd24組成物及びその使用 |
| JP2023093016A Active JP7662707B2 (ja) | 2018-05-14 | 2023-06-06 | 抗cd24組成物及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023093016A Active JP7662707B2 (ja) | 2018-05-14 | 2023-06-06 | 抗cd24組成物及びその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US12286485B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3813877A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7294758B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR20250122537A (cg-RX-API-DMAC7.html) |
| CN (2) | CN116589582A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2019269361C1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA202092306A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL278689B2 (cg-RX-API-DMAC7.html) |
| MX (3) | MX2020012091A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202010589YA (cg-RX-API-DMAC7.html) |
| TW (1) | TWI835794B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019222082A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA202006647B (cg-RX-API-DMAC7.html) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7137696B2 (ja) | 2019-05-14 | 2022-09-14 | プロヴェンション・バイオ・インコーポレイテッド | 1型糖尿病を予防するための方法および組成物 |
| JP2022538870A (ja) * | 2019-06-25 | 2022-09-06 | イチロフ テック リミテッド | 抗cd24抗体及びその使用 |
| KR20230092863A (ko) | 2020-06-11 | 2023-06-26 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
| KR20230143177A (ko) * | 2021-02-08 | 2023-10-11 | 안텐진 바이올로직스 리미티드 | 신규한 항-cd24 항체 |
| WO2022178163A2 (en) * | 2021-02-18 | 2022-08-25 | Health Research, Inc. | Antibody-derived t cell activating technologies |
| MX2023013851A (es) | 2021-05-24 | 2023-12-08 | Provention Bio Inc | Metodos para el tratamiento de diabetes tipo 1. |
| WO2023280042A1 (zh) * | 2021-07-06 | 2023-01-12 | 盛禾(中国)生物制药有限公司 | 一种抗cd24抗体及其应用 |
| CN118076625A (zh) * | 2021-09-28 | 2024-05-24 | 广州昂科免疫生物技术有限公司 | 包含071核心肽的融合蛋白及其用途 |
| CN113831412B (zh) * | 2021-10-13 | 2023-06-20 | 宜明昂科生物医药技术(上海)股份有限公司 | 靶向cd24的抗体及其制备和用途 |
| CN118369340A (zh) * | 2021-11-25 | 2024-07-19 | 盛禾(中国)生物制药有限公司 | 一种双特异性抗原结合蛋白 |
| AU2022404358A1 (en) * | 2021-12-07 | 2024-07-04 | Beijing Kanghong Biomedical Co., Ltd | Anti-cd24 antibody and use thereof |
| AU2023258034A1 (en) * | 2022-04-20 | 2024-11-07 | OncoC4, Inc. | Mutant cd24 proteins and uses thereof for prophylaxis and treatment of cancer |
| CN115947855B (zh) * | 2022-05-20 | 2023-10-27 | 杭州邦顺制药有限公司 | 抗cd24抗体的制备及其用途 |
| AU2023320486A1 (en) * | 2022-08-04 | 2025-02-20 | Memorial Hospital For Cancer And Allied Diseases | Anti-cd24 antibodies and uses thereof |
| JP2025535498A (ja) * | 2022-10-27 | 2025-10-24 | ベイジン ネオエックス バイオテック リミテッド | Cd24に対する抗体およびその使用 |
| CN120112561A (zh) * | 2022-11-01 | 2025-06-06 | 南京昂科免疫生物医药有限公司 | 一种cd24结合蛋白及其用途 |
| CN115960243B (zh) * | 2023-01-09 | 2025-05-06 | 中国药科大学 | 靶向cd24和cd3的双特异性抗体及其应用 |
| CN121311506A (zh) * | 2023-06-09 | 2026-01-09 | 天境生物科技(上海)有限公司 | 抗-cd24抗体及其用途 |
| EP4790070A1 (en) * | 2023-10-04 | 2026-08-12 | Daegu Gyeongbuk Institute of Science and Technology | Anti-cd24 antibody or antigen-binding fragment thereof, and use thereof |
| WO2025077809A1 (zh) * | 2023-10-12 | 2025-04-17 | 江苏融泰生物技术有限公司 | 抗体融合蛋白及应用 |
| WO2025085805A1 (en) * | 2023-10-20 | 2025-04-24 | OncoC4, Inc. | Anti-cd24/anti-cd3 bispecific binding proteins and uses thereof |
| TW202535944A (zh) * | 2023-11-08 | 2025-09-16 | 美商飛斯特醫療公司 | Cd24抗體 |
| WO2025151423A1 (en) * | 2024-01-08 | 2025-07-17 | OncoC4, Inc. | Anti-cd24 antibody drug conjugates and uses thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993014775A1 (en) * | 1992-01-31 | 1993-08-05 | Wright George L Jr | Monoclonal antibody pd41 and antigen associated with prostate adenocarcinomas |
| WO2004022597A1 (ja) * | 2002-09-04 | 2004-03-18 | Chugai Seiyaku Kabushiki Kaisha | Gpc3の血中可溶化n端ペプチドに対する抗体 |
| CN1894413A (zh) | 2003-03-26 | 2007-01-10 | 特鲁比昂药品公司 | 识别cd3或4-1bb的抗体或基因介导的肿瘤反应性淋巴细胞活化 |
| CA2584494A1 (en) * | 2007-03-27 | 2008-09-27 | Jeffrey A. Medin | Vector encoding therapeutic polypeptide and safety elements to clear transduced cells |
| WO2009063461A1 (en) | 2007-11-14 | 2009-05-22 | The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center | Methods of treating cancer using anti cd24 antibodies |
| TWI667346B (zh) | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | 促進抗原消失之具有經修飾的FcRn親和力之抗體 |
| ES2826445T3 (es) * | 2010-04-28 | 2021-05-18 | Oncolmmune Inc | Uso médico de CD24 soluble |
| EP2574627A1 (en) * | 2011-09-30 | 2013-04-03 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Particular uses of CD24 inhibitors |
| US9562110B2 (en) | 2012-11-21 | 2017-02-07 | Wuhan Yzy Biopharma Co., Ltd. | Bispecific antibody |
| MX377714B (es) | 2013-10-18 | 2025-03-11 | Regeneron Pharma | Composiciones que comprenden una combinación de un antagonista de vegf y un anticuerpo anti-ctla-a. |
| CN103819561A (zh) | 2014-01-22 | 2014-05-28 | 中国药科大学 | 抗cd24单克隆抗体、其可变区序列及其应用 |
| WO2016019969A1 (en) | 2014-08-08 | 2016-02-11 | Ludwig-Maximilians-Universität München | Subcutaneously administered bispecific antibodies for use in the treatment of cancer |
| US9804170B2 (en) * | 2015-02-09 | 2017-10-31 | Bristol-Myers Squibb Company | Antibodies to polyethylene glycol |
| CN105505869A (zh) * | 2015-12-21 | 2016-04-20 | 河南大学淮河医院 | 一种针对肿瘤干细胞的嵌合抗原受体t细胞 |
| EP3851457A1 (en) | 2016-01-21 | 2021-07-21 | Novartis AG | Multispecific molecules targeting cll-1 |
-
2019
- 2019-05-13 SG SG11202010589YA patent/SG11202010589YA/en unknown
- 2019-05-13 KR KR1020257026199A patent/KR20250122537A/ko active Pending
- 2019-05-13 AU AU2019269361A patent/AU2019269361C1/en active Active
- 2019-05-13 EA EA202092306A patent/EA202092306A1/ru unknown
- 2019-05-13 KR KR1020207033131A patent/KR102844265B1/ko active Active
- 2019-05-13 CN CN202310460291.1A patent/CN116589582A/zh active Pending
- 2019-05-13 CN CN201980032893.9A patent/CN112424441B/zh active Active
- 2019-05-13 EP EP19803135.3A patent/EP3813877A4/en active Pending
- 2019-05-13 JP JP2020564389A patent/JP7294758B2/ja active Active
- 2019-05-13 IL IL278689A patent/IL278689B2/en unknown
- 2019-05-13 MX MX2020012091A patent/MX2020012091A/es unknown
- 2019-05-13 US US17/055,248 patent/US12286485B2/en active Active
- 2019-05-13 TW TW108116423A patent/TWI835794B/zh active
- 2019-05-13 WO PCT/US2019/031983 patent/WO2019222082A1/en not_active Ceased
-
2020
- 2020-10-26 ZA ZA2020/06647A patent/ZA202006647B/en unknown
- 2020-11-11 MX MX2024015039A patent/MX2024015039A/es unknown
- 2020-11-11 MX MX2025002661A patent/MX2025002661A/es unknown
-
2023
- 2023-06-06 JP JP2023093016A patent/JP7662707B2/ja active Active
-
2025
- 2025-03-14 AU AU2025201864A patent/AU2025201864A1/en active Pending
- 2025-04-03 US US19/169,938 patent/US20250333532A1/en active Pending
- 2025-04-03 US US19/169,932 patent/US20250243292A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112955471B (zh) | Cd3抗体及其药物用途 | |
| CN110511278B (zh) | 抗b7-h6抗体、融合蛋白及其使用方法 | |
| DK1976880T3 (en) | Pharmaceutical compositions with resistance to soluble cea | |
| CN116261590B (zh) | 抗cd3抗体以及其用途 | |
| US20240197931A1 (en) | Radioimmunotherapy directed to ccr8 for depletion of tumor infiltrating regulatory t cells | |
| CN118987201A (zh) | 治疗癌症的抗pd-1抗体和双特异性抗cd20/抗cd3抗体组合 | |
| WO2021254481A1 (zh) | 抗Claudin18.2抗体以及其用途 | |
| JP2021510736A5 (cg-RX-API-DMAC7.html) | ||
| WO2020114479A1 (zh) | 多特异性蛋白分子 | |
| US20210040213A1 (en) | Immunomonotherapy for urothelial carcinoma | |
| JP2025148435A (ja) | ヒトがんの治療のためのモノクローナル抗体neo-201 | |
| US12173081B2 (en) | CD19/CD38 multispecific antibodies | |
| JP2025016452A (ja) | 癌の治療における放射免疫療法と免疫チェックポイント療法との組み合わせ | |
| Caracciolo et al. | Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia | |
| CA3249273A1 (en) | CD28 Bispecific Antibodies for Targeted T Lymphocyte Activation | |
| EP3092252A1 (en) | ANTIBODY TARGETING CELL SURFACE DEPOSITED COMPLEMENT PROTEIN C3d AND USE THEREOF | |
| JP2019535753A (ja) | 抗CD300f抗体およびその利用 | |
| KR20230028386A (ko) | 인간 질환의 치료를 위한 cd38 항체 | |
| JP2022523360A5 (cg-RX-API-DMAC7.html) | ||
| JP2025510642A5 (cg-RX-API-DMAC7.html) | ||
| CN118557748A (zh) | 使用抗cd123免疫缀合物的治疗方法 | |
| TW202005983A (zh) | 抗-人類pd-l1之抗體及其用途 | |
| CA3099974A1 (en) | Binding proteins and chimeric antigen receptor t cells targeting gasp-1 granules and uses thereof | |
| Clark et al. | Induction of multiple anti-c-erbB-2 specificities accompanies a classical idiotypic cascade following 2B1 bispecific monoclonal antibody treatment | |
| Garambois et al. | Fully human IgG and IgM antibodies directed against the carcinoembryonic antigen (CEA) Gold 4 epitope and designed for radioimmunotherapy (RIT) of colorectal cancers |